Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “

A number of other equities research analysts have also recently commented on the company. Raymond James Financial, Inc. cut Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and dropped their target price for the company from $21.00 to $18.00 in a research report on Tuesday, March 14th. Wells Fargo & Co restated an “outperform” rating and set a $29.00 target price (up from $22.00) on shares of Amphastar Pharmaceuticals in a research report on Wednesday, December 21st. Jefferies Group LLC set a $21.00 target price on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 14th. Piper Jaffray Companies dropped their target price on Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 14th. Finally, Needham & Company LLC dropped their target price on Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.29.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 14.27 on Friday. The company has a market capitalization of $656.75 million, a PE ratio of 64.86 and a beta of 1.74. Amphastar Pharmaceuticals has a 12-month low of $11.25 and a 12-month high of $21.75. The stock’s 50 day moving average price is $15.49 and its 200 day moving average price is $18.12.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, March 13th. The company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. The business earned $63.54 million during the quarter, compared to analyst estimates of $55.78 million. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. The company’s revenue was down 17.4% on a year-over-year basis. During the same quarter last year, the business posted $0.19 EPS. On average, equities research analysts forecast that Amphastar Pharmaceuticals will post $0.40 earnings per share for the current year.

Your IP Address:

Large investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans boosted its stake in Amphastar Pharmaceuticals by 2.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 19,440 shares of the company’s stock worth $358,000 after buying an additional 400 shares during the period. GSA Capital Partners LLP boosted its stake in Amphastar Pharmaceuticals by 212.4% in the fourth quarter. GSA Capital Partners LLP now owns 56,544 shares of the company’s stock worth $1,042,000 after buying an additional 38,444 shares during the period. New York State Teachers Retirement System boosted its stake in Amphastar Pharmaceuticals by 43.2% in the fourth quarter. New York State Teachers Retirement System now owns 19,896 shares of the company’s stock worth $366,000 after buying an additional 6,000 shares during the period. Trexquant Investment LP acquired a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $197,000. Finally, Dimensional Fund Advisors LP boosted its stake in Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock worth $14,753,000 after buying an additional 324,043 shares during the period. Hedge funds and other institutional investors own 49.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.